Skip to content
Graymedy Health technology human perspective
English
English Arabic
  • Home
  • Medicines
  • FDA approves obinutuzumab for adults with primary membranous nephropathy
Medicines

FDA approves obinutuzumab for adults with primary membranous nephropathy

Kidney disease approval

A urine specimen container. Illustrative photo: RDNE Stock project / Pexels.
A urine specimen container. Illustrative photo: RDNE Stock project / Pexels.

The U.S. Food and Drug Administration has approved obinutuzumab (Gazyva) for adults with primary membranous nephropathy who are at risk of disease progression. The treatment is intended to induce remission of proteinuria, the leakage of protein into urine. The FDA describes it as the first drug specifically approved for this condition in adults.

Primary membranous nephropathy is a rare immune-mediated kidney disease. Injury to the kidneys’ filtering units can allow protein to leak into urine, and people may experience swelling, fatigue, high blood pressure or other complications. The course varies, and clinicians assess the risk of progression when discussing treatment.

What the study found

The approval was supported by MAJESTY, an open-label, randomized phase 3 study of 142 adults. Participants received obinutuzumab or tacrolimus. At week 104, 36% in the obinutuzumab group achieved complete remission under the study definition, compared with 6% in the tacrolimus group. The endpoint included a low urine protein-to-creatinine ratio and stable estimated kidney function, with additional conditions concerning rescue treatment and discontinuation.

These figures describe a particular trial population and endpoint; they do not predict an individual patient’s outcome. The study compared the drug with tacrolimus, not every available approach to care.

Safety matters

The FDA says the prescribing information carries boxed warnings for hepatitis B reactivation and progressive multifocal leukoencephalopathy, a rare serious brain infection. Infusion-related reactions and upper respiratory infections were among the most common adverse reactions in the study. Patients should discuss screening, monitoring, benefits and risks with their kidney specialist rather than changing treatment on their own.

Understanding the condition

The kidney’s glomeruli act as filters, retaining substances the body needs while helping remove waste from the blood. In primary membranous nephropathy, an immune attack damages these filters. Protein can then escape into urine. The FDA describes a range of possible consequences, including swelling, high cholesterol, high blood pressure and, in some people, kidney failure.

Protein in urine is therefore not merely a laboratory curiosity. It is one way clinicians follow a disease that can affect kidney function over time. The amount of protein, kidney function and the person’s broader health all contribute to a risk assessment. An approval for people at risk of progression does not mean that every person with the condition should receive the same treatment.

How to interpret the comparison

MAJESTY followed participants for 104 weeks in its main study period. The FDA’s definition of complete remission required a urine protein-to-creatinine ratio no higher than 0.3 grams per gram, stable estimated glomerular filtration rate, and no rescue therapy, treatment failure or early discontinuation under the endpoint rules. The endpoint is more specific than simply saying a urine test improved.

The absolute difference between the reported groups was 30 percentage points. It is a comparison within this study, not a promise that 30 additional people in every hundred treated in routine practice will benefit. The study was open-label: participants and investigators knew which treatment was assigned. Its size, selected population and chosen comparator all matter when clinicians apply the results.

Obinutuzumab had already been approved for other conditions, including certain cancers and lupus nephritis. The new indication is specific to adults with primary membranous nephropathy at risk of progression. Approval and prescribing rules can differ outside the United States.

Questions for a care team

A patient might ask how their current urine protein and kidney function compare with previous results, what makes their disease likely to progress, and which treatment options fit their circumstances. It is also reasonable to ask what monitoring is planned during and after treatment, how response will be assessed and what to do if side effects occur.

The FDA identifies infusion reactions and upper respiratory tract infections as common adverse reactions in the study. The boxed warnings deserve a separate discussion because hepatitis B can reactivate and progressive multifocal leukoencephalopathy is a rare, serious brain infection. The complete prescribing information contains additional safety details. Decisions about screening, vaccination, other medicines and treatment timing belong with the treating clinician.

Remission is a goal measured over time, not an immediate guarantee. The trial results add an approved option and useful evidence for discussion; they do not replace individualized monitoring or justify stopping an existing medicine without medical advice.

Source: U.S. FDA: approval and study summary, posted November 13, 2026.

Featured image: urine specimen container; illustrative photograph by RDNE Stock project / Pexels.

Medicines

View more
Assorted tablets in blister packs
Why antibiotics are losing their power—and what helps protect them

Antibiotics have transformed the treatment of bacterial infections, but some bacteria are becoming harder to treat. Antimicrobial resistance occurs when microorganisms change and no longer respond to medicines that once worked against them. Antibiotic resistance concerns bacteria, not a person becoming resistant to a medicine. Resistant bacteria can spread between people and through animals, food and the environment. Infections caused by them may be more difficult to treat and can require different medicines or longer care. Antibiotics act against bacterial infections; they do not treat viruses such as those that cause colds and flu. A clinician can decide whether an antibiotic is appropriate, taking account of the illness and, when useful and available, diagnostic tests. Taking antibiotics when they are not needed contributes to the conditions in which resistance develops. Patients can help by taking antibiotics only when prescribed by a qualified health professional, following the prescribed instructions, and not sharing or saving medicines for another illness. If a treatment causes a problem or symptoms do not improve, contact the prescriber rather than changing it independently. Preventing infections through vaccination, hand hygiene and safe food and water also reduces the need for antimicrobials. World AMR Awareness Week runs from 18 to 24 November. The 2026 campaign calls for action across human, animal and environmental health because resistance does not respect those boundaries. Protecting effective medicines requires both access to appropriate treatment and responsible use. Sources: WHO antimicrobial resistance fact sheet and World AMR Awareness Week 2026.

Graymedy Editorial November 19, 2026 0
A pharmacist holds a bottle containing tablets

Generic medicines: why a different-looking pill can do the same job

A urine specimen container. Illustrative photo: RDNE Stock project / Pexels.

FDA approves obinutuzumab for adults with primary membranous nephropathy

Illustrative diabetes care supplies, including tablets and syringes. Photo: Nataliya Vaitkevich / Pexels; resized and framed.

Metformin and insulin: why diabetes medicines are not interchangeable

Assorted tablets in blister packs. Illustrative photograph: Polina Tankilevitch / Pexels.
Could Your Allergy Medicine Be Making You Sleepy?

Your runny nose has improved, but now you can barely keep your eyes open. If you recently took an allergy medicine, the two experiences may be connected. Some antihistamines can cause drowsiness. The effect varies by medicine and by person, and it is worth understanding before you drive, work with machinery or assume your tiredness has another cause. Why can antihistamines make you drowsy? Antihistamines are used to relieve allergy symptoms by blocking the effects of histamine. Some are more likely than others to make people sleepy. Examples of antihistamines that generally cause less sleepiness include loratadine, fexofenadine and cetirizine. Less sleepy does not mean guaranteed to be non-drowsy: individuals can respond differently. Diphenhydramine is an antihistamine that can cause drowsiness. It is also found in some combination products, which makes checking the active ingredients useful when you take more than one cold or allergy medicine. What should you do if you feel sleepy? Check the product label and speak with a pharmacist or clinician about your symptoms and possible alternatives. Tell them about all the medicines and supplements you use, including products bought without a prescription. Avoid driving or operating machinery if you feel drowsy. Alcohol can add to the sedating effect of diphenhydramine. Do not stop or change a prescribed medicine without discussing it with the person who prescribed it. Could something else be responsible? Yes. Allergies, disrupted sleep, other medicines and unrelated health conditions may also contribute to tiredness. If the drowsiness persists, is severe or is affecting your daily life, seek medical advice rather than assuming the antihistamine is the only cause. The takeaway An allergy medicine can be effective and still cause an unwanted effect. A pharmacist can help you review the ingredients and discuss an option suited to your circumstances. Sources: MedlinePlus: Antihistamines for allergies; MedlinePlus: Diphenhydramine. Illustrative photograph: Polina Tankilevitch / Pexels. The tablets are not identified as antihistamines.

Graymedy Editorial November 15, 2026 0
Skincare serum bottles. Photo: Polina Kovaleva / Pexels; illustrative products.

Retinol, retinoids and acne: what’s the difference?

Electron micrograph of hepatitis B virus particles.

Hibsago brings a finite-treatment option to hepatitis B, with close monitoring at its core

Educational kidney image for context; not a patient scan or a depiction of treatment response.

Ultomiris reaches IgA nephropathy—with a kidney-outcome question still open

Scanning electron micrograph of Mycobacterium tuberculosis bacteria; archival CDC image, not a sample from the lesion-penetration study.
For shorter TB treatment, a drug must reach the bacteria’s hiding place

GRAYMEDY RESEARCH ANALYSIS · November 8, 2026 A medicine can circulate in the bloodstream yet reach different parts of diseased tissue unevenly. An October tuberculosis study asks whether understanding that distribution can improve the design of shorter treatment regimens. The tissue-level question Jacqueline P. Ernest, Annamarie E. Bustion, Anu Patel and colleagues assembled lung-lesion distribution data for 24 drugs and drug candidates in rabbits with cavitary tuberculosis. Their Nature Communications paper, published October 14, 2026, combined these measurements with a lesion-penetration model validated using clinical data. The researchers linked local exposure with antibacterial activity and simulated coverage for shortened regimens examined in major phase 3 trials. They propose that combinations containing at least two drugs reaching bactericidal concentrations inside pulmonary cavities are more likely to meet clinical endpoints in people with cavitary disease. This is a translational modelling finding, not a newly approved treatment rule. Why blood concentration is an incomplete picture The paper focuses on a difficult location: the necrotic centre of a lung cavity. Measuring a drug in blood answers one question about exposure. Measuring whether it reaches a relevant tissue compartment answers another. A regimen can therefore look promising at one level of analysis while leaving important uncertainty at another. Graymedy’s interpretation is that regimen design should examine combinations in space as well as in time. The question becomes whether the medicines provide useful overlapping activity where bacteria persist, rather than simply whether several active agents appear on a prescription. That is a research design principle, not guidance to change an individual patient’s medicines. Prediction still needs prospective testing The study draws strength from connecting experimental distribution measurements, clinical validation and previous trial outcomes. But reproducing or explaining past outcomes differs from showing that a prospectively chosen new regimen improves future outcomes. That distinction matters whenever a model is proposed as a way to reduce uncertainty in expensive clinical development. Animal lesions cannot capture every feature of human disease. Patients also vary in disease extent, susceptibility patterns, concurrent illness and how medicines are absorbed and taken. A model may inform a trial without replacing the trial’s assessment of efficacy, safety and recurrence after treatment. What a useful next step would show A strong next test would specify a regimen using the modelling framework before knowing the clinical outcome, then evaluate it in an appropriate patient population. Researchers would need to define how cavitary disease is measured and whether predictions remain calibrated across relevant subgroups. The proposed two-drug cavity-coverage principle should likewise be treated as a hypothesis to examine across regimens and settings. More drugs, higher exposure and shorter duration are not automatically interchangeable. A promising distribution profile cannot by itself resolve toxicity or interactions. For patients, the immediate implication is understanding why treatment-shortening research remains demanding. A shorter course must still clear infection reliably and safely. This study offers a way to ask more precise questions before launching a trial; it does not authorize stopping or shortening prescribed treatment. The scientific contribution is a closer connection between pharmacology and the actual geography of disease. If that connection improves prospective prediction, it could help developers choose which combinations deserve the considerable effort of clinical testing. Sources and publication dates Ernest et al., Nature Communications, October 14, 2026; accepted article version Independent editorial analysis of published research; no interview or endorsement is implied. Image credit: Janice Carr / CDC, with Dr Ray Butler; PHIL 8438, 2006. Public domain. Original image source. GRAYMEDY RESEARCH ANALYSIS · November 8, 2026 A medicine can circulate in the bloodstream yet reach different parts of diseased tissue unevenly. An October tuberculosis study asks whether understanding that distribution can improve the design of shorter treatment regimens. The tissue-level question Jacqueline P. Ernest, Annamarie E. Bustion, Anu Patel and colleagues assembled lung-lesion distribution data for 24 drugs and drug candidates in rabbits with cavitary tuberculosis. Their Nature Communications paper, published October 14, 2026, combined these measurements with a lesion-penetration model validated using clinical data. The researchers linked local exposure with antibacterial activity and simulated coverage for shortened regimens examined in major phase 3 trials. They propose that combinations containing at least two drugs reaching bactericidal concentrations inside pulmonary cavities are more likely to meet clinical endpoints in people with cavitary disease. This is a translational modelling finding, not a newly approved treatment rule. Why blood concentration is an incomplete picture The paper focuses on a difficult location: the necrotic centre of a lung cavity. Measuring a drug in blood answers one question about exposure. Measuring whether it reaches a relevant tissue compartment answers another. A regimen can therefore look promising at one level of analysis while leaving important uncertainty at another. Graymedy’s interpretation is that regimen design should examine combinations in space as well as in time. The question becomes whether the medicines provide useful overlapping activity where bacteria persist, rather than simply whether several active agents appear on a prescription. That is a research design principle, not guidance to change an individual patient’s medicines. Prediction still needs prospective testing The study draws strength from connecting experimental distribution measurements, clinical validation and previous trial outcomes. But reproducing or explaining past outcomes differs from showing that a prospectively chosen new regimen improves future outcomes. That distinction matters whenever a model is proposed as a way to reduce uncertainty in expensive clinical development. Animal lesions cannot capture every feature of human disease. Patients also vary in disease extent, susceptibility patterns, concurrent illness and how medicines are absorbed and taken. A model may inform a trial without replacing the trial’s assessment of efficacy, safety and recurrence after treatment. What a useful next step would show A strong next test would specify a regimen using the modelling framework before knowing the clinical outcome, then evaluate it in an appropriate patient population. Researchers would need to define how cavitary disease is measured and whether predictions remain calibrated across relevant subgroups. The proposed two-drug cavity-coverage principle should likewise be treated as a hypothesis to examine across regimens and settings. More drugs, higher exposure and shorter duration are not automatically interchangeable. A promising distribution profile cannot by itself resolve toxicity or interactions. For patients, the immediate implication is understanding why treatment-shortening research remains demanding. A shorter course must still clear infection reliably and safely. This study offers a way to ask more precise questions before launching a trial; it does not authorize stopping or shortening prescribed treatment. The scientific contribution is a closer connection between pharmacology and the actual geography of disease. If that connection improves prospective prediction, it could help developers choose which combinations deserve the considerable effort of clinical testing. Sources and publication dates Ernest et al., Nature Communications, October 14, 2026; accepted article version Independent editorial analysis of published research; no interview or endorsement is implied. Featured graphic: original Graymedy evidence diagram, not a study image or patient photograph.

Graymedy Editorial November 8, 2026 0
National Cancer Institute anatomical illustration of the larynx, vocal cords and nearby structures

A new head-and-neck cancer approval brings an option—and an evidence question

Pink and purple stained prostate adenocarcinoma tissue viewed under a microscope

Talazoparib moves earlier in prostate cancer—with a genetic test at the centre

Black-and-white scanning electron micrograph of rounded Enterococcus faecalis bacteria

Sixteen bacterial strains, one clinical question: can SER-155 prevent bloodstream infections?

STAY INFORMED

Notifications

New stories, news and e-newspapers, as they become public.

Browser notifications

Get an alert on this device when we publish. You can turn this off anytime.

Loading notification settings…

Latest updates

No new publications yet. Check back soon.